Details For Selected Brain Tumor Treatment

Sponsored By

Cedars-Siani Medical Center Brain Tumor Program

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase II study of CDX-110 with radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme

		Phase:		Phase 2

		Treatment ID#:		1899 2007-0263

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Sometimes Allowed newly diagnosed glioblastoma multiforme

		Last Updated:		04/03/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:		CDX-110 is a vaccine based on a peptide from a variant of the epidermal growth factor (EGFRvIII), which is present in multiple cancer types but rare in normal tissue. Eligible patients need documented EGFRvIII expression in tumor tissue.

		Treatment Type:		Chemotherapy Immunological, Biological or Targeted Therapy

		Contact:		Jan Esenwein Program Coordinator, Brain Tumor Program MD Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030- USA Phone: (713)745-2264 Fax: (713)794-4999 E-mail: jesenwei@mdanderson.org Website: www.mdanderson.org/diseases/braincancer/

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By